Eli Lilly

Showing 15 posts of 203 posts found.

NICE recommends two new treatments for inflammatory arthritis

June 18, 2021
Medical Communications Eli Lilly, NICE, Novartis

NICE has recommended two new treatments for axial spondyloarthritis, an underdiagnosed and debilitating type of inflammatory arthritis. Ixekizumab (also known …

Eli Lilly and MiNA Therapeutics to collaborate on saRNA research

May 12, 2021
Research and Development Eli Lilly

Eli Lilly and MiNA Therapeutics have announced a global research collaboration to develop novel drug candidates using MiNA’s proprietary small …


Eli Lilly to collaborate with diabetes tech companies on insulin pen

May 10, 2021
Sales and Marketing Eli Lilly, diabetes

Eli Lilly has signed strategic international agreements with four companies – Dexcom, Glooko, myDiabby Healthcare, and Roche – with the …

Eli Lilly front sign

Lilly’s COVID-19 drug has EUA revoked in favour of combination therapy

April 19, 2021
Sales and Marketing COVID-19, Eli Lilly, FDA, covid-19 treatment, lilly, pharma, pharma news

The FDA have revoked Emergency Use Authorization (EUA) of Eli Lilly’s bamlanivimab drug for the treatment of COVID-19, per the …

Eli Lilly building

Lilly’s ulcerative colitis treatment meets all key endpoints in Phase III trial

March 17, 2021
Research and Development Eli Lilly, Phase III trial, lilly, mirikizumab, ulcerative colitis

Eli Lilly’s mirikizumab treatment for ulcerative colitis (UC) patients has met the primary endpoints and all key secondary endpoints in …

Eli Lilly building

Eli Lilly’s COVID-19 treatment combination 87% effective in Phase III trial

March 11, 2021
COVID-19, Eli Lilly, covid-19 treatment

Eli Lilly has shown positive results in its Phase III combination drug trial, which reduced hospitalisations and deaths related to …


Lilly’s cancer drug Retsevmo gets UK approval for multiple indications

March 10, 2021
Research and Development Cancer, Eli Lilly, MHRA

The MHRA has granted conditional marketing authorisation for Eli Lilly’s Retsevmo (selpercatinib) as monotherapy for a number of cancer indications.


CHMP recommends Lilly’s bamlanivimab for COVID-19 patients

March 8, 2021
Sales and Marketing COVID-19, EMA, Eli Lilly

The EMA’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive scientific opinion for Eli Lilly’s bamlanivimab …


Eli Lilly’s diabetes drug tirzepatide reduces blood glucose and weight in Phase III trials

February 18, 2021
Eli Lilly, diabetes

Eli Lilly’s tirzepatide led to significant haemoglobin A1C (HbA1C) and body weight reductions from baseline in adults with type 2 …

Eli Lilly front sign

University of Glasgow and Lilly sign £4.6m immunological disease partnership

February 15, 2021
Sales and Marketing Eli Lilly, University of Glasgow, arthritis, fibrosis, lilly, uofg

The University of Glasgow and Eli Lilly and Company have entered into a research collaboration, across four diseases, worth £4.6 …


FDA grants emergency authorisation to Lilly’s COVID-19 antibody combination

February 11, 2021
COVID-19, Eli Lilly

The FDA has granted emergency use authorisation for Eli Lilly’s antibodies bamlanivimab (LY-CoV555) 700mg and etesevimab (LY-CoV016) 1400mg, to be …


Lilly’s antibody could reduce COVID-19 risk by 80%, trial shows

January 22, 2021
Medical Communications COVID-19, Eli Lilly

Eli Lilly’s neutralising antibody bamlanivimab significantly reduced the risk of contracting symptomatic coronavirus among residents and staff of long-term care …


Eli Lilly’s Alzheimer’s drug slows clinical decline in Phase II trial

January 11, 2021
Sales and Marketing Alzheimer's, Eli Lilly

Eli Lilly’s donanemab has shown significant slowing of decline in a composite measure of cognition and daily function in patients …


Eli Lilly scoops up gene therapy specialist Prevail Therapeutics for a potential $1.04bn

December 16, 2020
Research and Development, Sales and Marketing Eli Lilly, Prevail, acquisition

Eli Lilly has struck a deal to acquire Prevail Therapeutics in a transaction that could be valued at up to …


Lilly’s tirzepatide generates significant reductions in weight and blood sugar in type 2 diabetes patients

December 10, 2020
Research and Development Eli Lilly, diabetes, tirzepatide

Eli Lilly has announced new data for its glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide, showing …

Latest content